Patents Represented by Attorney, Agent or Law Firm Robert W. Stevenson
  • Patent number: 7304114
    Abstract: Liquid rubbers that are ordinarily immiscible in liquid thermoset resins can be made miscible by the addition of at least one non-functional aromatic end-group to the polymer chains of such liquid rubber compositions. Such addition may be initiated by high-temperature peroxides in non-functional aromatic solvents. The liquid rubbers are found to improve the fracture toughness of cured thermoset resins while maintaining dimensional and heat resistance.
    Type: Grant
    Filed: August 20, 2004
    Date of Patent: December 4, 2007
    Assignee: Rohm and Haas Company
    Inventor: Edward Ewart LaFleur
  • Patent number: 6942898
    Abstract: An aqueous coating composition having improved adhesion to friable surfaces including an emulsion polymer of certain compositions and certain acid numbers having a glass transition temperature of ?20 C to 100 C and an average particle diameter less than 120 nanometers; and 0.25-10%, by weight based on emulsion polymer weight, water-soluble alkoxylated amine is provided. In addition a method for for improving adhesion to friable surfaces by using the aqueous coating compositions of the invention is provided.
    Type: Grant
    Filed: July 10, 2003
    Date of Patent: September 13, 2005
    Assignee: Rohm and Haas Company
    Inventors: Matthew Stewart Gebhard, Bradley Keith Hageman
  • Patent number: 6610854
    Abstract: Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes are useful for inducing or promoting apotosis and for arresting uncontrolled neoplastic cell proliferation, and are specifically useful in the arresting and treatment of neoplasias, including precancerous and cancerous lesions.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: August 26, 2003
    Assignees: Cell Pathways, Inc., University of Arizona
    Inventors: Gerhard J. Sperl, Paul Gross, Klaus Brendel, Gary A. Piazza, Rifat Pamukcu
  • Patent number: 6569638
    Abstract: This invention provides a method to identify compounds potentially useful for the treatment and prevention of neoplasia in mammals. The phosphodiesterase inhibitory activity of a compound is determined along with its ability to elevate JNK kinase activity. Growth inhibitory and apoptosis inducing effects on cultured tumor cells are also determined. Compounds that exhibit phosphodiesterase inhibition, an ability to elevate JNK kinase activity, growth inhibition and apoptosis induction are desirable for the treatment of neoplasia.
    Type: Grant
    Filed: March 3, 2000
    Date of Patent: May 27, 2003
    Assignee: Cell Pathways, Inc
    Inventors: I. Bernard Weinstein, W. Joseph Thompson, Jae-Won Soh, Li Liu, Han Li
  • Patent number: 6562830
    Abstract: Derivatives of 2-phenyl quinazolinones are useful for the treatment of patients having precancerous lesions. These compounds are also useful to inhibit growth of neoplastic cells.
    Type: Grant
    Filed: November 9, 1999
    Date of Patent: May 13, 2003
    Assignee: Cell Pathways, Inc.
    Inventors: Rifat Pamukcu, Gary A. Piazza
  • Patent number: 6555547
    Abstract: This invention provides a method for treating a patient with neoplasia by an adjuvant therapy that includes treatment with an antineoplastic vinca alkaloid derivative.
    Type: Grant
    Filed: February 28, 2000
    Date of Patent: April 29, 2003
    Assignee: Cell Pathways, Inc.
    Inventors: Rifat Pamukcu, Joseph M. Lobacki
  • Patent number: 6538029
    Abstract: A method of treating renal cell carcinoma in a mammal with that disease comprising administering to the mammal a physiologically effective amount of an inhibitor of PDE10.
    Type: Grant
    Filed: May 29, 2002
    Date of Patent: March 25, 2003
    Assignee: Cell Pathways
    Inventors: W. Joseph Thompson, John R. Fetter, Robert E. Bellet, Han Li
  • Patent number: 6500610
    Abstract: This invention provides pharmaceutical compositions containing compounds for the treatment of neoplasia in mammals. The phosphodiesterase inhibitory activity of a compound is determined along with COX inhibitory activity. Growth inhibitory and apoptosis inducing effects on cultured tumor cells are also determined. Compounds that exhibit phosphodiesterase inhibiton, growth inhibition and apoptosis induction, but prefereably not substantial prostaglandin inhibitory activity, are desirable for the treatment of neoplasia.
    Type: Grant
    Filed: October 8, 1999
    Date of Patent: December 31, 2002
    Assignee: Cell Pathways, INC
    Inventors: Rifat Pamukcu, Gary A. Piazza
  • Patent number: 6486155
    Abstract: A method for inhibiting neoplasia, particularly cancerous and precancerous lesions by exposing the affected cells to isoquinoline derivatives.
    Type: Grant
    Filed: November 24, 1998
    Date of Patent: November 26, 2002
    Assignee: Cell Pathways Inc
    Inventors: Rifat Pamukcu, Gary A. Piazza
  • Patent number: 6486158
    Abstract: [4,5]-Fused-3,6 disubstituted-pydidazines of Formula I are useful for inducing or promoting apoptosis and for arresting uncontrolled neoplastic cell proliferation, and are specifically useful in the arresting and treatment of neoplasia: wherein Y1 and Y2 are independently selected from the group consisting of (CH2)n,—C(X)—NH—,—(CH2)n—C(X)—O—, and X is O or S; R1 is selected from the group consisting of lower alkyl, lower alkenyl, lower alkynyl, and substituted or unsubstituted phenyl, pyridinyl, and the like; R2 is selected from the group consisting of substituted or unsubstituted phenyl, benzyl, pyridinyl, and the like; “A” is a benzene ring fused with the pyridazine ring; and R3 is independently selected in each instance form the group consisting of halogen, lower alkyl, and the like.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: November 26, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Xiaojing Wang, Gerhard Sperl, Paul Gross, Rifat Pamukcu, Gary A. Piazza
  • Patent number: 6479493
    Abstract: Substituted condensation products of -benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of type I diabetes.
    Type: Grant
    Filed: August 23, 2001
    Date of Patent: November 12, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Clark M. Whitehead, Keith A. Earle, Hector W. Alila, W. Joseph Thompson
  • Patent number: 6479520
    Abstract: Derivatives of phenyl pyridinone are useful for the treatment of patients having precancerous lesions. These compounds are also useful to inhibit the growth of neoplastic cells.
    Type: Grant
    Filed: March 8, 2000
    Date of Patent: November 12, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Gary Piazza, Rifat Pamukcu
  • Patent number: 6472420
    Abstract: This invention provides a method for treating a patient with neoplasia by an adjuvant therapy that includes treatment with a paclitaxel derivative.
    Type: Grant
    Filed: January 3, 2002
    Date of Patent: October 29, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Rifat Pamukcu, Kerstin B. Menander
  • Patent number: 6465494
    Abstract: Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of cystic fibrosis.
    Type: Grant
    Filed: August 24, 2001
    Date of Patent: October 15, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Keith A. Earle, Hector W. Alila, Clark M. Whitehead, W. Joseph Thompson
  • Patent number: 6455703
    Abstract: 1,3,6-Trihydro-6-Aza-3-Oxapentalen-2-One Derivatives which have the following formula: wherein R1, R2, R3, R4, R5, Y, X, m, and n are as defined in the specification.
    Type: Grant
    Filed: December 6, 2000
    Date of Patent: September 24, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Gerhard Sperl, Rifat Pamukcu
  • Patent number: 6440981
    Abstract: A method for inhibiting the growth of neoplastic cells by exposure to 2,9-disubstituted purin-6-ones.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: August 27, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Rifat Pamukcu, Gary A. Piazza
  • Patent number: 6432950
    Abstract: Benzothienopyrimidine derivatives for inducing or promoting apoptosis and for arresting uncontrolled neoplastic cell proliferation, and specifically for arresting and treating neoplasia, including precancerous and cancerous lesions.
    Type: Grant
    Filed: July 12, 2000
    Date of Patent: August 13, 2002
    Assignee: Cell Pathways
    Inventors: Rifat Pamukcu, Gary A. Piazza
  • Patent number: 6426349
    Abstract: Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes are useful for inducing or promoting apotosis and for arresting uncontrolled neoplastic cell proliferation, and are specifically useful in the arresting and treatment of neoplasias, including precancerous and cancerous lesions.
    Type: Grant
    Filed: December 20, 2000
    Date of Patent: July 30, 2002
    Assignee: Cell Pathway and the University of Arizona
    Inventors: Gerhard J. Sperl, Paul Gross, Klaus Brendel, Gary A. Piazza, Rifat Pamukeu
  • Patent number: 6420410
    Abstract: A method for inhibiting neoplastic cells and related conditions by exposing them to N,N′-substituted benzimidazol-2-ones.
    Type: Grant
    Filed: August 16, 2000
    Date of Patent: July 16, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Gerhard Sperl, Ulrich Ixkes, Rifat Pamukcu, Gary A. Piazza
  • Patent number: 6410584
    Abstract: A method for inhibiting neoplastic cells and related conditions by exposing them to substituted indole derivatives.
    Type: Grant
    Filed: November 25, 1998
    Date of Patent: June 25, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Rifat Pamukcu, Gary A. Piazza